(Q34714765)

4 August 2017

1 reference

title

Pharmacologic therapy of lipid disorders in the elderly (English)

1 reference

4 August 2017

Aronow WS

1

1 reference

4 August 2017

publication date

1 July 2002

1 reference

The American Journal of Geriatric Cardiology

4 August 2017

published in

1 reference

4 August 2017

volume

11

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

247-256

1 reference

Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

The evolving role of statins in the management of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Asymptomatic coronary artery disease in patients with stroke. Prevalence, prognosis, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Prevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women > or = 62 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Hypertriglyceridemia, insulin resistance, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1076-7460.2002.00816.X

10.1111/J.1076-7460.2002.00816.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference